Structural optimization elaborates novel potent Akt inhibitors with promising anticancer activity

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Targeting Akt kinase is a validated strategy for cancer therapy, particularly for aggressive hematologic malignancies.
• Previous pyrrolo[2,3-d]pyrimidine derivatives showed potential as Akt inhibitors.

Purpose of the Study:

• To explore novel Akt inhibitors through structural optimization of existing pyrrolo[2,3-d]pyrimidine compounds.
• To identify potent inhibitors for aggressive hematologic malignancies.

Main Methods:

• Structural optimization of 4-(piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine derivatives.
• Synthesis and evaluation of novel pyrrolopyrimidine based phenylpiperidine carboxamides.
• Assessment of antiproliferative effects, apoptosis induction, cell cycle arrest, and downstream Akt signaling modulation in cancer cell lines (Jeko-1) and primary patient tumor cells.

Main Results:

• A novel series of pyrrolopyrimidine based phenylpiperidine carboxamides with potent Akt1 inhibition was discovered.
• Compound 10h demonstrated robust antiproliferative effects against mantle cell lymphoma cell lines and primary patient tumor cells.
• Low micromolar doses of 10h induced apoptosis and G2/M cell cycle arrest, and downregulated phosphorylation of Akt targets GSK3β and S6 in Jeko-1 cells.

Conclusions:

• Novel pyrrolopyrimidine derivatives, particularly compound 10h, are potent Akt inhibitors with significant therapeutic potential for aggressive hematologic malignancies.
• Compound 10h warrants further investigation as a targeted therapy for mantle cell lymphoma and other cancers driven by Akt signaling.